

Press release

NeuroVive Pharmaceutical AB (publ)
556595-6538



NeuroVive – company presentations January 2019

Lund, Sweden, 18 January 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) informs on its scheduled company presentation for January 2019.

Since the extraordinary general meeting of NeuroVive Pharmaceutical AB on Thursday, January 17, 2019 decided to issue a rights issue with a subscription period from January 23, 2019 until February 6, 2019, the Company wishes to remind of the company presentations NeuroVive gives in January 2019.

NeuroVive's CEO Erik Kinnman will present the company and the business at the following events. For more information, see further under the respective links below.

Monday, 21 January **Swedish Shareholders' Association - Aktiekväll, theme Life Science**
Stockholm Hotell Birger Jarl, Birger Jarlsgatan 61A, at 17.30
<https://www.aktiespararna.se/aktiviteter/aktiekvallen-stockholm-21-januari>

Tuesday, 22 January **Swedish Shareholders' Association - Aktiekväll**
Gothenburgh Elite Park Avenue, Kungsporsavenyn 36, at 17.30
<https://www.aktiespararna.se/aktiviteter/aktiekvallen-goteborg>

Tuesday, 29 January **Aktiedagen, Swedish Shareholders' Association**
Lund Medicon Village, Scheelevägen 2, 08.00 – 18.20
<https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-29-januari-0>

For further information on the Company, a newly recorded interview with NeuroVive's CEO Erik Kinnman is available on Cornelia News: <http://cornelianews.com/c-talk/milstolpar-uppnadda-nu-tar-neurovive-in-124-miljoner-kr/>.

The information was submitted for publication, through the agency of the contact person set out below, at 08.30 a.m. CET on 18 January 2019.

For more information please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

info@neurovive.com, www.neurovive.com

For news subscription, please visit <http://www.neurovive.com/press-releases/subscription-page/>

Follow us on [LinkedIn](#)

Subscribe to our [YouTube channel](#)

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. Investors can find Real-Time quotes and market information for the company at www.otcmartets.com/stock/NEVPF/quote

Press release

NeuroVive Pharmaceutical AB (publ)
556595-6538



About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. Investors can find Real-Time quotes and market information for the company at www.otcmarkets.com/stock/NEVPF/quote